Table 5

Visual field progression of subjects

Brimonidine (n = 31)Timolol (n = 28)p Value
Number of patients with progressing locations6 (20%)5 (17.9%)0.84
Progressing subjects onlyBrimonidine (n = 6)Timolol (n = 5)p Value
Number of progressing locations0.25
    Mean (SD)1.83 (0.41)1.6 (1.34)
    Range1–21–4
    Median21
Slope of progressing locations (dB/year)0.08
    Mean (SD)−1.59 (0.85)−2.18 (1.16)
    Range−3.4 to −1.0−4.2 to −1.2
    Median−1.1−1.65